Skip to main
BWAY
BWAY logo

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd has demonstrated a significant improvement in its operational efficiency, reflected by an over 50% increase in equipment utilization rates since the establishment of recent investments. The company is poised for enhanced revenue growth due to additional strategic investments that have been secured, enabling it to expand its market reach and operational capacity. Furthermore, the successful initial equity financing transaction serves as a favorable model for future financial undertakings, underpinning a robust framework for ongoing growth and development in the noninvasive neurostimulation sector.

Bears say

The negative outlook on BrainsWay's stock is driven by several fundamental risks, including the slower-than-projected adoption of its Deep TMS systems, which could hinder revenue growth. Additionally, the company's reliance on expanding reimbursement and market access poses a significant threat to its financial stability if it fails to secure necessary funding and support from healthcare payers. Finally, the ongoing risk of long-term dilution may impact shareholder value, particularly if BrainsWay cannot successfully advance its clinical trials for additional indications.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.